Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: Results from two US treatment centres

British Journal of Haematology

Volumn 165, Issue 1, 2014, Pages 39-48

  Robinson, Don ^a   Reynolds, Matthew ^b   Casper, Corey ^c   Dispenzieri, Angela ^d   Vermeulen, Jessica ^e   Payne, Krista ^f   Schramm, Judy ^c   Ristow, Kay ^d   Desrosiers, Marie Pierre ^f   Yeomans, Karen ^f   Teltsch, Dana ^b   Swain, Richard ^b   Habermann, Thomas M ^d   Rotella, Philip ^b   Van de Velde, Helgi ^g  

^a Janssen Global Services   (United States)

^b EVIDERA   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d MAYO CLINIC   (United States)

^e Janssen Research and Development   (Netherlands)

^f UNITED BIOSOURCE CORPORATION   (Canada)

^g JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Castleman disease; Epidemiology; Healthcare utilization; Lymphoproliferative disorder; Treatment

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LENALIDOMIDE; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ADULT; AGE; AGED; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; BIOCHEMISTRY; BLOOD TRANSFUSION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUCASIAN; CLINICAL FEATURE; DEMOGRAPHY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; NIGHT SWEAT; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; SEX RATIO; UNITED STATES; YOUNG ADULT;

CASTLEMAN DISEASE; EPIDEMIOLOGY; HEALTHCARE UTILIZATION; LYMPHOPROLIFERATIVE DISORDER; TREATMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GEOGRAPHY, MEDICAL; GIANT LYMPH NODE HYPERPLASIA; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; PREVALENCE; UNITED STATES; YOUNG ADULT;

EID: 84896054346     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12717     Document Type: Article

References (20)

1. Brandt, S.J., Bodine, D.M., Dunbar, C.E. & Nienhuis, A.W. (1990) Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. The Journal of Clinical Investigation, 86, 592-599.
2. Casper, C. (2005) The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. British Journal of Haematology, 129, 3-17.
3. Cinnamon, J., Schuurman, N. & Crooks, V.A. (2008) A method to determine spatial access to specialized palliative care services using GIS. BioMed Central Health Services Research, 8, 140.
4. Dispenzieri, A. (2008) Castleman disease. In: Rare Hematologic Malignancies (ed. by S.M. Ansell ), pp. 293-330. Springer Science+Business Media, LLC, New York, NY.
5. Dispenzieri, A., Armitage, J.O., Loe, M.J., Geyer, S.M., Allred, J., Camoriano, J.K., Menke, D.M., Weisenburger, D.D., Ristow, K., Dogan, A. & Habermann, T.M. (2012) The clinical spectrum of Castleman's disease. American Journal of Hematology, 87, 997-1002.
6. Durie, B., Binder, G., Pashos, C., Khan, Z., Hussein, M. & Borrello, I. (2013) Total cost comparison in relapsed/refractory multiple myeloma. Journal of Medical Economics, 16, 614-622.
7. El-Osta, H.E. & Kurzrock, R. (2011) Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist, 16, 497-511.
8. Higgs, G. (2004) A literature review of the use of GIS-based measures of access to health care services. Health Services and Outcomes Research Methodology, 5, 119-139.
9. InGauge Mutual Healthcare Solutions (2012) Physicians' Fee and Coding Guide. Ingauge Mutual Healthcare Solutions, Atlanta, GA.
10. Kojima, M., Nakamura, N., Tsukamoto, N., Otuski, Y., Shimizu, K., Itoh, H., Kobayashi, S., Kobayashi, H., Murase, T., Masawa, N., Kashimura, M. & Nakamura, S. (2008) Clinical implications of idiopathic multicentric castleman disease among Japanese: a report of 28 cases. International Journal of Surgical Pathology, 16, 391-398.
11. McLafferty, S.L. (2003) GIS and health care. Annual Review of Public Health, 24, 25-42.
12. Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., Hara, M., Taguchi, H., Kimura, Y., Kato, Y., Asaoku, H., Kumagai, S., Kodama, F., Nakahara, H., Hagihara, K., Yoshizaki, K. & Kishimoto, T. (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood, 106, 2627-2632.
13. van Rhee, F., Stone, K., Szmania, S., Barlogie, B. & Singh, Z. (2010a) Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clinical Advances in Hematology and Oncology, 8, 486-498.
14. van Rhee, F., Fayad, L., Voorhees, P., Furman, R., Lonial, S., Borghaei, H., Sokol, L., Crawford, J., Cornfeld, M., Qi, M., Qin, X., Herring, J., Casper, C. & Kurzrock, R. (2010b) Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. Journal of Clinical Oncology, 28, 3701-3708.
15. Schuurman, N., Fiedler, R.S., Grzybowski, S.C. & Grund, D. (2006) Defining rational hospital catchments for non-urban areas based on travel-time. International Journal of Health Geographics, 5, 43.
16. Schwartzberg, L.S., Stepanski, E.J., Walker, M.S., Mathias, S., Houts, A.C. & Fortner, B.V. (2009) Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. Supportive Care in Cancer, 17, 91-98.
17. Talat, N. & Schulte, K.M. (2011) Castleman's disease: systematic analysis of 416 patients from the literature. Oncologist, 16, 1316-1324.
18. Talat, N., Belgaumkar, A.P. & Schulte, K.M. (2012) Surgery in Castleman's disease: a systematic review of 404 published cases. Annals of Surgery, 255, 677-684.
19. Tina Shih, Y.C., Xu, Y. & Elting, L.S. (2007) Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer, 110, 678-685.
20. ® accessed March 18, 2013 from http://www.micromedexsolutions.com/home/dispatch.